CA2249390A1 - Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor - Google Patents

Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Info

Publication number
CA2249390A1
CA2249390A1 CA002249390A CA2249390A CA2249390A1 CA 2249390 A1 CA2249390 A1 CA 2249390A1 CA 002249390 A CA002249390 A CA 002249390A CA 2249390 A CA2249390 A CA 2249390A CA 2249390 A1 CA2249390 A1 CA 2249390A1
Authority
CA
Canada
Prior art keywords
melanoma
specific
cytotoxic lymphocytes
uses therefor
restricted cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002249390A
Other languages
French (fr)
Other versions
CA2249390C (en
Inventor
Craig L. Slingluff
Donald F. Hunt
Jeffrey Shabanowitz
Andrea L. Cox
Victor H. Engelhard
David Kittlesen
Jonathan Skipper
Ronald C. Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2249390A1 publication Critical patent/CA2249390A1/en
Application granted granted Critical
Publication of CA2249390C publication Critical patent/CA2249390C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Melanoma-specific, A1-restricted CTL epitopes have been identified in tyrosinase, and may be used in conjunction with other A1- A2- and/or A3-restricted epitopes of tyrosinase, pMel-17 and other melanoma antigens in the design of vaccines.
CA002249390A 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor Expired - Fee Related CA2249390C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1397296P 1996-03-19 1996-03-19
US60/013,972 1996-03-19
US2762796P 1996-10-04 1996-10-04
US60/027,627 1996-10-04
PCT/US1997/004958 WO1997034613A1 (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Publications (2)

Publication Number Publication Date
CA2249390A1 true CA2249390A1 (en) 1997-09-25
CA2249390C CA2249390C (en) 2007-12-18

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249390A Expired - Fee Related CA2249390C (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Country Status (4)

Country Link
EP (1) EP0921805A4 (en)
AU (1) AU712820B2 (en)
CA (1) CA2249390C (en)
WO (1) WO1997034613A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (en) * 1997-05-07 2003-05-16 Centre Nat Rech Scient PEPTIDE ANALOGS AND THEIR USES IN PARTICULAR IN PHARMACEUTICAL COMPOSITIONS AND FOR DIAGNOSIS
CA2334958A1 (en) * 1998-12-24 2000-07-06 New York Medical College Peptide mimics useful for treating disease
CA2362295A1 (en) * 1999-02-11 2000-08-17 Genzyme Corporation Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
JP4540033B2 (en) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド Methods for inducing and / or enhancing immune responses against tumor antigens
AU1440601A (en) * 1999-10-29 2001-05-14 Argonex Pharmaceuticals, Inc. Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1355926A2 (en) * 2000-05-31 2003-10-29 Genzyme Corporation Therapeutic compounds for ovarian cancer
WO2002060390A2 (en) * 2001-01-04 2002-08-08 Yale University Induction of immune responses to isoaspartyl-modified antigens
DE60238864D1 (en) 2001-11-07 2011-02-17 Mankind Corp FOR EPITOPES OF ANTIGENIC ENCODING EXPRESSION VECTORS AND METHOD FOR THEIR DESIGN
DE102005041616B4 (en) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
EP2232258A4 (en) 2007-12-05 2011-01-05 Govt Of The U S A As Represented By The Secretary Of The Dept Of Health & Human Services Improved viral protein quantification and vaccine quality control therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006916B1 (en) * 1977-09-28 1981-07-08 National Research Development Corporation Immunological preparations incorporating mhc antigens and their production
WO1994014459A1 (en) * 1992-12-22 1994-07-07 Ludwig Institute For Cancer Research Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
EP0966480A2 (en) * 1997-01-30 1999-12-29 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
AU712820B2 (en) 1999-11-18
AU2424397A (en) 1997-10-10
CA2249390C (en) 2007-12-18
WO1997034613A1 (en) 1997-09-25
EP0921805A4 (en) 2002-06-26
EP0921805A1 (en) 1999-06-16

Similar Documents

Publication Publication Date Title
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
CA2118928A1 (en) Saponin-antigen conjugates and the use thereof
CA2189882A1 (en) Papillomavirus vaccines
EP1564824A3 (en) Energy conversion composition
CA2267072A1 (en) Reconstituted human anti-hm1.24 antibody
WO1996017072A3 (en) Recombinant alphavirus vectors
EP0592202A3 (en) D-ketohexose 3-epimerase, and its preparation and uses.
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
CA2249390A1 (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
AU9075591A (en) N-halochitosans, their preparation and uses
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
CA2182889A1 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
AU662213B2 (en) Turbine and turbocharger using the same
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
AUPO007396A0 (en) Ebv ctl epitopes
AU7495796A (en) Novel oligopeptides, the preparation and use thereof
AU1086888A (en) Primary biliary cirrhosis autoantigen
WO1996002572A3 (en) Antigenic polypeptide sequence of factor viii, fragments and/or epitopes thereof
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU2001273950A1 (en) Antibodies against native gp96, production and use thereof
ZA9610510B (en) Novel peptides, the preparation and use thereof.
AR244752A1 (en) Azo-colouring, the procedure for preparing it and its use.
ZA98587B (en) A novel antigen from P. aeruginosa, and its use in medicine.
AU8113691A (en) The class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties, and vaccines containing same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed